Log-in
Register now
Register now
Log-in

Nordic Life Science Days 2016
14-15 september 2016
Waterfront, Stockholm, Sweden

© 2024 Bionordic. All Rights Reserved

Register now
Log-in

Logo
Register now
Log-in
Register now
Log-in

Latest news in cooperation with Nordic Life Science

News

Ulrika Hammarström awarded Uppsala’s Entrepreneur of the Year

26 April 2024 | 6:35 am
Ulrika Hammarström awarded Uppsala's Entrepreneur of the Year
Recently, the annual Entrepreneur’s Gala took place at Uppsala Castle to honor companies that showed exceptional performance during the past year and the Entrepreneur of the Year award was awarded to Ulrika Hammarström, CEO and Founder of Scandinavian CRO (SCRO). This prize is awarded by jury to an entrepreneur who has performed above and beyond […]
News

CNS diseases – Is the last complex medical enigma about to be solved?

24 April 2024 | 1:02 pm
CNS diseases – Is the last complex medical enigma about to be solved?
News

Novel AI model detects 90% of lymphatic cancer cases

24 April 2024 | 8:56 am
Novel AI model detects 90% of lymphatic cancer cases
Researchers at Chalmers University of Technology in Sweden have carried out one of the largest studies to date using AI (artificial intelligence)-assisted image analysis of lymphoma. “An AI-based computer system for interpreting medical images also contributes to increased equality in healthcare by giving patients access to the same expertise and being able to have their […]
News

Spago Nanomedical reports favorable data

24 April 2024 | 8:33 am
Mats Hansen
The company has announced data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 demonstrates superior anti-tumor effect compared to standard cancer drugs with a low and acceptable level of radiotoxicity observed, states the company. “Triple-negative breast cancer is a very aggressive disease with poor prognosis. The […]
News

AstraZeneca’s Voydeya approved in the EU as add-on treatment

24 April 2024 | 4:35 am
Marc Dunoyer
Voydeya has been approved as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of […]
News

The winners of HackHERHealth

23 April 2024 | 1:27 pm
The winners of HackHERHealth
In the beginning of March, Sahlgrenska Science Park, GoCo Health Innovation City, AstraZeneca, and other members of Health Innovation West invited participants, students, researchers, tech enthusiasts, life science experts, entrepreneurs, and others to a femtech innovation hackathon, a hackaton focused on reducing the gender health gap and advancing women’s health. Initiators of the hackaton were […]
News

Mia Phillipson – Pioneering immunotherapies

23 April 2024 | 4:52 am
Mia Phillipson – Pioneering immunotherapies
Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur. “Most of all, I am a scientist. Yes, absolutely. This is my main occupation and the one in which I have the most expertise,” says Mia Phillipson, who […]
News

Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer

22 April 2024 | 8:19 am
Nykode initiates Phase 2 trial in second line HPV16-positive cervical cancer
The company has announced the initiation of the Phase 2 clinical trial VB-C-04. The trial evaluates VB10.16, the company’s off-the-shelf therapeutic cancer vaccine candidate for HPV16-positive cancers, alone or in combination with Roche’s checkpoint inhibitor atezolizumab (Tecentriq) in patients with HPV16positive, PD-L1-positive, recurrent, or metastatic cervical cancer. “Initiating the VB10.16 trial for HPV16-positive cervical cancer […]
News

BioArctic and Eisai sign research evaluation agreement

22 April 2024 | 8:08 am
BioArctic and Eisai sign research evaluation agreement
The two companies have entered into an agreement regarding BAN2802, a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer’s disease. “I […]
News

Building and bridging the most innovative life science cluster in the EU

17 April 2024 | 1:06 pm
Building and bridging the most innovative life science cluster in the EU
Boston’s Kendall Square, close to Massachusetts Institute of Technology (MIT), is known as “The most innovative square mile on the planet” and, apart from our preference for the metric system, there just might be something we could learn from the Americans. One of the recommendations is that public and private stakeholders, inspired by the success […]

© 2024 SwedenBIO. All Rights Reserved

Legal Notices

© 2024 Bionordic. All Rights Reserved

Legal Notices